biOasis Technologies Inc. (the “Company”), (TSX.V: BTI) is pleased to announce the appointment of Dr. Leigh Anderson as a member of the Company’s Scientific Advisory Board. “Dr. Anderson has vast expertise in the area of diagnostics and biomarkers and their application to human disease and our team is very excited to have him aboard”? Rob Hutchison CEO.
Dr. Anderson is the founder and CEO of the Plasma Proteome Institute (“PPI”), Washington DC (www.plasmaproteome.org). The Institute aims to foster a comprehensive exploration of the proteins of human blood plasma (the plasma proteome) and the application of novel protein measurements in clinical diagnostics. Prior to founding PPI, Dr. Anderson was Chief Scientific Officer at Large Scale Biology Corporation (Nasdaq: LSBC), whose proteomics division he founded in 1985 (as Large Scale Biology) prior to its merger in 1999 with Biosource Technologies. At LSBC, he developed the first automated two-dimensional electrophoresis technology platform for proteomics research and pioneered a range of applications in drug discovery, toxicology and in identification of surrogate markers for different diseases.
Dr. Anderson currently serves on the Board of Directors of Luna Innovations (a developer of novel materials and sensors) and was previously a member of the boards of Dade Behring Holdings (a global diagnostics company) and LSBC. He also serves on the advisory boards of the UVic-Genome BC Proteomics Centre (University of Victoria, BC Canada) and Better Biomarkers of Acute and Chronic Allograft Rejection, a Genome Canada Initiative for Human Health (Vancouver, BC Canada). Dr Anderson is also on the editorial board of the scientific journal Molecular and Cellular Proteomics and is a principal of the Anderson Forschung Group.
Dr. Anderson holds more than 30 patents and has written a book and over 130 scientific publications, mainly in the areas ofproteomics and its applications to biomedicine.
About the Company
biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the development and commercialization of diagnostics and therapeutics related to neurological diseases. It has extensive and comprehensive intellectual property (“IP”) which it obtained from the University of British Columbia. The Company’s initial area of focus will be on the utilization of the IP to pursue a biomarker for the diagnosis of Alzheimer’s disease. The IP has been corroborated in double blinded and successive multi-site clinical trials.
According to the Centers for Disease Control and Prevention (“CDC”), Alzheimer’s disease was listed as the “underlying cause of death” for 65,829 Americans in 2004. It was the seventh leading cause of death for people of all ages and the fifth leading cause of death in people age 65 and older.
To find out more about biOasis Technologies Inc. visit www.bioasis.ca.
“The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.”
On Behalf of the Board of Directors
Robin Hutchison, Director and CEO